Switzerland· 67633002
Miglustat Dipharma 100 mg, capsule
A miglustat product containing miglustatum, registered in Switzerland by Dipharma SA and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 18 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Miglustat is registered in 18 of 19 countries.
Countries holding a registration under ATC A16AX06 (miglustat), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 10 of them publish a price we can compare per daily dose
Miglustat · ATC A16AX06
18 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of miglustat costs, country by country.
Normalised to the WHO defined daily dose (0.3 g), so markets compare like for like.
- Switzerland: $225.28 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Miglustat · price per daily dose (0.3 g)
USD · FX 28 Sept 2026
- CH Switzerland$225.28
The record
At a glance
Swissmedic (Switzerland)- Active substance
- miglustatum
- Manufacturer
- Dipharma SA
- Country
- Switzerland (CH)
- ATC code
- A16AX06
- ATC class
- Miglustat
- Defined daily dose
- 0.3 g, O
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680676330026Blist 84 StkCHF 4422
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
1 interaction on record for miglustat.
Graded by severity as the source publishes them — 1 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Miglustat · interactions on record
1 record
- 1 moderate
Most severe, free to view
- ImigluceraseA16AB02moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Miglustat in 17 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaMIGLUSTAT ACCORDACCORD HEALTHCARE POLSKA Sp. z o.o., Varšava
- FinlandMiglustat AccordOrifarm Oy
- ItalyMIGLUSTAT ACCORDACCORD HEALTHCARE SLU
- PolandMiglustat AccordAccord Healthcare Polska Sp. z o.o.
- SpainMIGLUSTAT ACCORD 100 MG CAPSULAS DURAS EFGAccord Healthcare S.L.U.
- NetherlandsMiglustat Dipharma 100 mg harde capsulesDipharma Arzneimittel GmbH
- FranceMIGLUSTAT ACCORD 100 mg, géluleACCORD HEALTHCARE FRANCE
- United KingdomMiglustat 100mg capsulesFlynn Pharma Ltd
Authorised across Europe · EMA
The same active substance is authorised in 20 EEA countries. Names it is sold under:
- Austria · Miglustat G.L.
- Bulgaria · Миглустат G.L.
- Cyprus · Miglustat Accord
- Czechia · Miglustat Accord
- Germany · Miglustat Accord, Miglustat Axunio
- Denmark · Miglustat Bluefish, Miglustat Waymade
- Spain · Miglustat Accord, Miglustat Waymade
- Finland · Miglustat Accord, Miglustat Waymade
- France · Miglustat Accord, Miglustat Bluefish
- United Kingdom (Northern Ireland) · Miglustat Accord Healthcare, Miglustat Dipharma
- Iceland · Miglustat Dipharma, Opfolda
- Italy · Miglustat Accord, Miglustat Waymade
- Liechtenstein · Miglustat Dipharma, Opfolda
- Netherlands · Miglustat G.L., Miglustat Waymade
- Norway · Miglustat Bluefish, Miglustat Dipharma
- Poland · Miglustat, Miglustat Accord
- Portugal · Miglustato Accord
- Romania · Miglustat Accord
- Sweden · Miglustat, Miglustat Bluefish
- Slovakia · Miglustat Accord, Miglustat G.L. Pharma
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ae84758b-2c53-4d8f-a723-0ddd59f4c11a GET /v1/drugs/ae84758b-2c53-4d8f-a723-0ddd59f4c11a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "miglustatum 100 mg",
"valid_from": "2025-03-01",
"limitations": "[{\"description\":\"Zur Behandlung von erwachsenen Patienten mit leichter bis mittelschwerer Form des Morbus Gaucher Typ 1, für welche eine Enzymsubstitutionstherapie nicht möglich ist.\",\"costApproval\":null,\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2020-11-01\"}]",
"galenic_form": "Kaps 100 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2020-11-01",
"self_retention_pct": 10
}See everything about miglustat.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.